Cooley Capital Markets Co-Chair Quoted on Biotech IPOs

Charlie Kim, Cooley partner and co-chair of the firm’s capital markets practice, was quoted at length by Law360 regarding the market for biotech initial public offerings (IPOs) in 2024. Cooley was noted for its role in two of the top five biotech IPOs – including its representation of the underwriters in CG Oncology’s upsized $437 million IPO, the largest biotech IPO year to date, as well as its work representing Alto Neuroscience on its $147.9 million IPO.

Read the article (subscription required)

Cooley also was noted for representing ACELYRIN, Abivax and Neumora Therapeutics in 2023.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.